Wakeman SE, Green TC, Rich J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat Med Nature Publishing Group. 2020;26:819–20.
British Columbia Coroners Service Death Review Panel. A Review of Illicit Drug Toxicity Deaths [Internet]. 2022 Mar p. 1–60. https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divorce/deaths/coroners-service/death-review-panel/review_of_illicit_drug_toxicity_deaths_2022.pdf
Darke S, Ross J, Zador D, Sunjic S. Heroin-related deaths in New South Wales, Australia, 1992–1996. Drug Alcohol Depend. 2000;60:141–50.
Darke S, Duflou J. The toxicology of heroin-related death: estimating survival times. Addiction. 2016;111:1607–13.
Davidson PJ, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR. Fatal heroin-related overdose in San Francisco, 1997–2000: a case for targeted intervention. J Urban Health. 2003;80:261–73.
Gerostamoulos J, Staikos V, Drummer OH. Heroin-related deaths in Victoria: a review of cases for 1997 and 1998. Drug Alcohol Depend. 2001;61:123–7.
Lynn TM, Lynn E, Keenan E, Lyons S. Trends in injector deaths in ireland, as recorded by the national drug-related deaths index, 1998–2014. J Stud Alcohol Drugs. 2018;79:286–92.
O’Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and u-47700 - 10 states, July-December 2016. MMWR Morb Mortal Wkly Rep. 2017;66:1197–202.
Stam NC, Gerostamoulos D, Smith K, Pilgrim JL, Drummer OH. Challenges with take-home naloxone in reducing heroin mortality: a review of fatal heroin overdose cases in Victoria, Australia. Clin Toxicol (Phila). 2018;1–6.
Wojcicki JM. Dying alone: the sad irrelevance of naloxone in the context of solitary opiate use. Addiction. 2019;114:574–5.
Bmore Power. Fentanyl is here. Go slow. Have a plan. 2019 [cited 2019 Sep 24]. https://www.goslow.org/
Bennett AS, Golub A, Elliott L. A behavioral typology of opioid overdose risk behaviors among recent veterans in New York City. PLoS ONE. 2017;12: e0179054.
Genberg BL, Astemborski J, Piggott DA, Woodson-Adu T, Kirk GD, Mehta SH. The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: A rapid phone survey in Baltimore. Maryland Drug Alcohol Depend. 2021;221: 108584.
Hagan H, Campbell JV, Thiede H, Strathdee SA, Ouellet L, Latka M, et al. Injecting alone among young adult IDUs in five US cities: evidence of low rates of injection risk behavior. Drug Alcohol Depend. 2007;91(Suppl 1):S48-55.
Hayashi K, Wood E, Dong H, Buxton JA, Fairbairn N, DeBeck K, et al. Awareness of fentanyl exposure and the associated overdose risks among people who inject drugs in a Canadian setting. Drug Alcohol Rev. 2021;
Karamouzian M, Papamihali K, Graham B, Crabtree A, Mill C, Kuo M, et al. Known fentanyl use among clients of harm reduction sites in British Columbia. Canada Int J Drug Policy. 2020;77: 102665.
Khuat OTH, Morrow M, Nguyen TNN, Armstrong G. Social context, diversity and risk among women who inject drugs in Vietnam: descriptive findings from a cross-sectional survey. Harm Reduct J. 2015;12:35.
Latkin CA, Dayton L, Davey-Rothwell MA, Tobin KE. Fentanyl and drug overdose: perceptions of fentanyl risk, overdose risk behaviors, and opportunities for intervention among people who use opioids in Baltimore, USA. Subst Use Misuse. 2019;1–9.
Morissette C, Cox J, De P, Tremblay C, Roy E, Allard R, et al. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention. Int J Drug Policy. 2007;18:204–12.
Papamihali K, Yoon M, Graham B, Karamouzian M, Slaunwhite AK, Tsang V, et al. Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia. Canada Harm Reduct J. 2020;17:90.
Rouhani S, Park JN, Morales KB, Green TC, Sherman SG. Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence. Harm Reduct J. 2019;16:39.
Vazan P, Mateu-Gelabert P, Cleland CM, Sandoval M, Friedman SR. Correlates of staying safe behaviors among long-term injection drug users: psychometric evaluation of the staying safe questionnaire. AIDS Behav. 2012;16:1472–81.
Wechsberg WM, Cavanaugh ER. Differences found between women injectors in and out of treatment: implications for interventions. Drugs Soc. 1998;13:63–79.
Wood E, Tyndall MW, Spittal PM, Li K, Kerr T, Hogg RS, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ. 2001;165:405–10.
Zahnow R, Winstock AR, Maier LJ, Levy J, Ferris J. Injecting drug use: gendered risk. Int J Drug Policy. 2018;56:81–91.
Winiker AK, Tobin KE, Gicquelais RE, Owczarzak J, Latkin C. When you’re getting high… you just don’t want to be around anybody. A qualitative exploration of reasons for injecting alone: perspectives from young people who inject drugs. Subst Use Misuse. 2020;55:2079–86.
Bohnert ASB, Walton MA, Cunningham RM, Ilgen MA, Barry K, Chermack ST, et al. Overdose and adverse drug event experiences among adult patients in the emergency department. Addict Behav. 2018;86:66–72.
Gicquelais RE, Jannausch M, Bohnert ASB, Thomas L, Sen S, Fernandez AC. Links between suicidal intent, polysubstance use, and medical treatment after non-fatal opioid overdose. Drug Alcohol Depend. 2020;212: 108041.
Latkin CA, Gicquelais RE, Clyde C, Dayton L, Davey-Rothwell M, German D, et al. Stigma and drug use settings as correlates of self-reported, non-fatal overdose among people who use drugs in Baltimore. Maryland Int J Drug Policy. 2019;68:86–92.
Fendrich M, Becker J, Hernandez-Meier J. Psychiatric symptoms and recent overdose among people who use heroin or other opioids: Results from a secondary analysis of an intervention study. Addict Behav Rep. 2019;10: 100212.
Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019 [cited 2021 May 23];16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957118/
Small W, Kerr T, Charette J, Schechter MT, Spittal PM. Impacts of intensified police activity on injection drug users: evidence from an ethnographic investigation. Int J Drug Policy. 2006;17:85–95.
White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94:961–72.
Day C. Benzodiazepines in combination with opioid pain relievers or alcohol: greater risk of more serious ED visit outcomes. The CBHSQ Report [Internet]. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2013 [cited 2022 Mar 15]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK384672/
Jones CM, Paulozzi LJ, Mack KA. Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63:881–5.
Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 2015;49:493–501.
Gicquelais RE, Mezuk B, Foxman B, Thomas L, Bohnert ASB. Justice involvement patterns, overdose experiences, and naloxone knowledge among men and women in criminal justice diversion addiction treatment. Harm Reduct J. 2019;16:46.
Ashrafioun L, Bohnert ASB, Jannausch M, Ilgen MA. Evaluation of the current opioid misuse measure among substance use disorder treatment patients. J Subst Abuse Treat. 2015;55:15–20.
Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130:144–56.
Fernandez AC, Bush C, Bonar EE, Blow FC, Walton MA, Bohnert ASB. Alcohol and drug overdose and the influence of pain conditions in an addiction treatment sample. J Addict Med. 2019;13:61–8.
Luoma JB, Nobles RH, Drake CE, Hayes SC, O’Hair A, Fletcher L, et al. Self-stigma in substance abuse: development of a new measure. J Psychopathol Behav Assess. 2013;35:223–34.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.
Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–6.
Centers for Disease Control and Prevention. Overdose Deaths Accelerating During COVID-19 [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Feb 23]. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html
Never Use Alone [Internet]. [cited 2022 Mar 22]. https://neverusealone.com/
Brave Cooperative. BRAVE [Internet]. BRAVE. [cited 2022 Mar 22]. https://www.brave.coop
Harocopos A, Gibson BE, Saha N, McRae MT, See K, Rivera S, et al. First 2 months of operation at first publicly recognized overdose prevention centers in US. JAMA Netw Open. 2022;5: e2222149.
Kral AH, Lambdin BH, Wenger LD, Davidson PJ. Evaluation of an unsanctioned safe consumption site in the United States. New Engl J Med. 2020;383:589–90.
Collins AB, Boyd J, Czechaczek S, Hayashi K, McNeil R. (Re)shaping the self: an ethnographic study of the embodied and spatial practices of women who use drugs. Health Place. 2020;63: 102327.
Link BG. Understanding labeling effects in the area of mental disorders: an assessment of the effects of expectations of rejection. Am Sociol Rev. 1987;52:96–112.
Bardwell G, Boyd J, Kerr T, McNeil R. Negotiating space & drug use in emergency shelters with peer witness injection programs within the context of an overdose crisis: a qualitative study. Health Place. 2018;53:86–93.
Chang JS, Behar E, Coffin PO. Narratives of people who inject drugs on factors contributing to opioid overdose. Int J Drug Policy. 2019;74:26–32.
Cruz MF, Mantsios A, Ramos R, Case P, Brouwer KC, Ramos ME, et al. A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities. AIDS Behav. 2007;11:253–62.
Moore D. Governing street-based injecting drug users: a critique of heroin overdose prevention in Australia. Soc Sci Med. 2004;59:1547–57.
Rhodes T, Watts L, Davies S, Martin A, Smith J, Clark D, et al. Risk, shame and the public injector: a qualitative study of drug injecting in South Wales. Soc Sci Med. 2007;65:572–85.
Hatzenbuehler ML, Phelan JC, Link BG. Stigma as a fundamental cause of population health inequalities. Am J Public Health. 2013;103:813–21.
Wagner KD, Oman RF, Smith KP, Harding RW, Dawkins AD, Lu M, et al. “Another tool for the tool box? I’ll take it!”: feasibility and acceptability of mobile recovery outreach teams (MROT) for opioid overdose patients in the emergency room. J Subst Abuse Treat. 2020;108:95–103.
Canada M, Formica S. Implementation of a post-overdose quick response team in the rural Midwest: a team case study. J Commun Saf Well-Being. 2022;7:59–66.
United States Drug Enforcement Administration. Counterfeit prescription pills containing fentanyls: a global threat. 2016 Jul p. 9. Report No.: DEA-DCT-DIB-021–16. https://www.dea.gov/sites/default/files/docs/Counterfeit%2520Prescription%2520Pills.pdf
United States Drug Enforcement Administration. DEA Issues Public Safety Alert on Sharp Increase in Fake Prescription Pills Containing Fentanyl and Meth [Internet]. 2021 [cited 2022 Mar 23]. https://www.dea.gov/press-releases/2021/09/27/dea-issues-public-safety-alert